Estrogen and progesterone have different roles in menopause hormone therapy. Estrogen can relieve hot flashes and other menopause symptoms; a progestogen is generally needed to protect the uterine lining when systemic estrogen is prescribed to someone with a uterus. Understanding that distinction helps explain why prescriptions differ after hysterectomy, why schedules vary, and why an over-the-counter cream cannot simply replace a prescribed component. The right combination depends on the exact treatment and your medical history, rather than a general promise to balance hormones.
Begin with the anatomy that affects treatment
The uterus contains the endometrium, the lining that thickens and sheds during menstrual cycles. Systemic estrogen can stimulate that tissue after menopause as well. Without adequate protection, this stimulation can increase the risk of endometrial overgrowth and cancer. That is why the presence of a uterus is one of the first questions in an HRT assessment. ACOG’s hormone therapy guidance explains the usual need for combined treatment.
A hysterectomy removes the uterus, but it does not always remove the ovaries. Removing the ovaries can cause an abrupt loss of ovarian hormones; removing only the uterus does not necessarily do so. If the details of prior surgery are unclear, obtaining the operative history is more useful than guessing from the absence of periods.
Estrogen addresses symptoms through several formulations
Systemic estrogen is delivered through products such as pills, patches, gels, and sprays. It is particularly effective for hot flashes and night sweats and can help prevent bone loss during treatment. Some vaginal products provide systemic treatment, while low-dose vaginal products primarily address local symptoms. The medicine’s name and intended use determine which category it belongs to.
Estrogen does not become exempt from endometrial considerations because it is absorbed through the skin. Someone with a uterus using a systemic estradiol patch generally still needs appropriate protection. Our estrogen route comparison discusses why route affects some risks and practical issues while leaving this central requirement in place. A prescriber should explain how every component of the regimen fits together.
Progesterone is one member of a larger group
“Progestogen” is the umbrella term for substances with progesterone-like effects. It includes progesterone itself and synthetic progestins. Micronized progesterone refers to a formulation processed to improve its delivery; the word does not establish that it is suitable for every patient or free of adverse effects.
In combined menopause therapy, the progestogen’s central job is to oppose estrogen’s effects on the endometrium. The choice of molecule, route, dose, and duration all matter. A clinician may also consider tolerability and the expected bleeding pattern. The Menopause Society’s position statement discusses adequate endometrial protection and formulation differences. Marketing that calls a product “natural” does not answer whether it provides the protection required by a specific estrogen regimen.
Cyclic and continuous schedules create different expectations
Some combined regimens use progestogen for part of a cycle, while others use it every day. These approaches are often described as cyclic or sequential and continuous combined therapy. The choice can depend on whether periods are still occurring, time since menopause, the prescribed products, and individual preferences.
Bleeding can differ between schedules. A planned withdrawal bleed may occur with a cyclic regimen, whereas a continuous regimen may aim to avoid scheduled bleeding after an adjustment period. Ask the prescriber to describe the expected pattern in plain language. Knowing the schedule does not remove the need to report bleeding that is unusually heavy, persistent, or otherwise outside the agreed expectations. Do not change the number of progestogen days on your own.
Estrogen alone after hysterectomy still needs a full review
Without a uterus, routine endometrial protection is generally unnecessary, so estrogen alone is often used. That does not make treatment an automatic choice. The reason for hysterectomy, any residual endometrial tissue, endometriosis history, prior cancer, and other medical factors may influence the recommendation.
The distinction also matters when interpreting research. A study of estrogen alone in participants who had hysterectomies is not the same as a study of combined estrogen and progestin in people with a uterus. Risks cannot be transferred between the groups without considering the treatment and population. If an online article says simply that “HRT increases” or “HRT decreases” a risk, ask which regimen it actually studied before applying the statement to your prescription.
Specific exceptions should be identified by name
An approved combination of conjugated estrogens and bazedoxifene offers systemic treatment with a different mechanism for endometrial protection. Bazedoxifene is a selective estrogen receptor modulator, often abbreviated SERM. It is not the same thing as progesterone and is not a reason to omit protection from an unrelated estrogen prescription. The 2022 position statement identifies this formulation-specific exception.
Another distinct situation is low-dose vaginal estrogen. Routine progestogen is generally not required with these local products, although long-term randomized endometrial safety data are more limited. These are prescribing distinctions, not interchangeable shortcuts. If a regimen appears to omit progesterone despite a uterus being present, ask which product-specific reason applies rather than adding or stopping medicine independently.
Low-dose vaginal estrogen follows a different framework
Vaginal dryness, burning, and discomfort with penetration can be treated locally when appropriate. Low-dose vaginal estrogen has less systemic exposure than treatments intended to act throughout the body. Its usual lack of a routine progestogen requirement should not be extended to every vaginal product: a systemic vaginal ring is a different treatment.
Postmenopausal bleeding still requires evaluation during local estrogen use. “Low dose” does not mean a symptom can be ignored or that all medical histories carry the same considerations. People with a history of hormone-sensitive cancer should discuss local treatment with their care team. The vaginal versus systemic estrogen article explains these differences and when nonhormonal options may be tried first.
Bioidentical describes a molecule, not a quality guarantee
A hormone described as bioidentical has the same molecular structure as a hormone produced by the body. Some FDA-approved estradiol and progesterone products meet that description. The term therefore does not mean a medicine must be custom compounded, and it does not prove a product is safer than approved alternatives.
ACOG recommends FDA-approved menopause products over routinely prescribing compounded bioidentical preparations when approved options are available. Compounded products do not undergo the same premarket review for safety, effectiveness, and manufacturing quality. There can be specific clinical reasons for compounding, but those reasons should be explicit. ACOG’s clinical consensus on compounded therapy addresses the evidence and why hormone testing promoted for custom dosing has important limitations.
Creams and laboratory targets cannot substitute for protection
Do not assume that applying a progesterone cream from a retail shelf provides the same endometrial protection as a prescribed regimen. The relevant questions are whether the formulation is reliably absorbed, whether the delivered amount is adequate for the estrogen exposure, and whether the regimen has supporting evidence. A label using familiar hormone names does not settle those questions.
Likewise, a saliva or urine result labeled “balanced” does not prove the uterine lining is protected. ACOG does not recommend adjunct hormone testing as a basis for prescribing or dosing compounded menopause therapy. Bring all hormone products and supplements to the consultation, including creams obtained outside the prescribing practice. Unreported products can make it difficult to understand both exposure and side effects.
Tolerability should be discussed without removing essential treatment
People can experience breast tenderness, bleeding changes, headaches, or other unwanted effects during HRT. The specific pattern and timing matter. If a symptom appears during the progestogen portion of a cyclic regimen, recording that pattern may help the clinician reconsider the formulation or schedule. It does not establish on its own that progesterone is the only possible cause.
Do not continue systemic estrogen while silently dropping the prescribed protection because one component feels inconvenient or unpleasant. Contact the prescriber for a coordinated adjustment. Ask whether an alternative approved product, a different schedule, or a different treatment approach could address the problem. The goal is a regimen that is both tolerable and appropriate for your anatomy and health history.
Unexpected bleeding deserves a defined response
Before treatment, establish what bleeding should be reported and how to contact the practice. Record whether bleeding is scheduled, new after a period without bleeding, associated with sex, or heavier than expected. Persistent or unexplained bleeding should not be dismissed because you are taking a progestogen.
ACOG updated its approach to postmenopausal bleeding evaluation in April 2026, recommending both transvaginal ultrasound and endometrial tissue sampling initially for most patients. The actual evaluation depends on the clinical situation. ACOG’s updated guidance announcement is a reminder that an older internet rule about a thin ultrasound measurement cannot replace individualized assessment. Severe bleeding with weakness or faintness requires urgent attention rather than a routine medication review.
Questions that clarify the combination
Ask the prescriber: Is my estrogen systemic or local? Do I need endometrial protection? Which medicine provides it? Is the schedule continuous or cyclic? What bleeding pattern is expected, and what should prompt an earlier review? Also ask what to do if a dose is missed or a medicine runs out.
A useful plan names each product and its purpose without requiring you to infer the rationale from a bundle or label. Keep a written list when more than one prescription is involved. Our HRT monitoring guide covers how symptom response and bleeding history shape follow-up. Understanding the separate roles of estrogen and progestogen makes the treatment easier to use correctly and easier to reassess when circumstances change.
Related reading
- Menopause Hormone Therapy: Benefits, Options, and Questions to Ask
- Estrogen Patch vs. Pill: Comparing Menopause HRT Routes
- HRT Risks and Benefits: Age, Timing, and Personal Medical History
- HRT Testing and Follow-Up: Symptoms, Bleeding, and Laboratory Questions
- Menopausal skin care and changing skin needs
- Estriol face cream versus menopause hormone therapy
Educational information. Individual treatment selection, prescription directions, and follow-up belong with the treating clinician. Linked guidance and source versions checked September 15, 2026. Medication instructions and evidence can differ by formulation and clinical use. Photographs are illustrative and do not show treatment outcomes.
